Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework
Endocrinology and Metabolism · 30.06.2026 · 41 (3) · 351-357
DOI: 10.3803/enm.2026.3080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 30.06.2026. Verfasst von Suk Kyeong Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Se…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Practice Guidelines as Topic, Hypoglycemic Agents, Evidence-Based Medicine. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
The pharmacological management of type 2 diabetes mellitus has changed markedly over the past decade, largely in response to evidence generated by cardiovascular and renal outcome trials. Although contemporary guidelines are informed by a broadly shared evidence base, they differ in how they organize treatment concepts and translate evidence into clinical algorithms. This review compares major diabetes guidelines from the American Diabetes Association (ADA), the National Institute for Health and Care Excellence (NICE), the Japan Diabetes Society (JDS), and the Korean Diabetes Association (KDA), with particular attention to pharmacological algorithms, comorbidity-driven treatment strategies, and the conceptual principles underlying each framework. The ADA guideline uses a person-centered, risk-based approach that prioritizes sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists for patients with cardiorenal disease. The NICE guideline applies a more structured strategy, recommending early dual or triple therapy within a cost-effectiveness framework. The JDS guideline emphasizes pathophysiology-based treatment selection tailored to East Asian populations. The KDA guideline retains a glycemia-centered treatment structure while incorporating comorbidity-based decision-making and allowing early, flexible combination therapy. Thus, despite substantial convergence in the evidence base, these guidelines differ in how cardiovascular risk, glycemic control, and pathophysiological heterogeneity are incorporated into treatment decisions. The KDA framework can be viewed as a pragmatic hybrid model that integrates these dimensions and is further extended by recent consensus efforts addressing disease severity and pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. mfsily@naver.com.
Zitieren
APA
Kim, S. K., Kim, D. L., Song, K., Kang, S., Lee, B. W., & Choi, J. H. (2026). Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework. Endocrinology and Metabolism, 41(3), 351-357. https://doi.org/10.3803/enm.2026.3080
Vancouver
Kim SK, Kim DL, Song K, Kang S, Lee BW, Choi JH. Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework. Endocrinology and Metabolism. 2026;41(3):351-357. doi:10.3803/enm.2026.3080
BibTeX
@article{Kim2026,
author = {Kim, Suk Kyeong and Kim, Dong-Lim and Song, Keeho and Kang, Shinae and Lee, Byung-Wan and Choi, Jong Han},
title = {Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {3},
pages = {351--357},
doi = {10.3803/enm.2026.3080}
}
EUVIMED